Close Menu

NEW YORK – Metabolomics firm Numares said Thursday that it has signed an agreement with Bruker to bring nuclear magnetic resonance-based diagnostics to market.

The collaboration aims to transition Regensburg, Germany-based Numares' Axinon platform, which combines NMR measures of metabolites with AI analysis, from research to routine clinical use.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.